NCT04215211Recruiting
MR Based Survival Prediction of Glioma Patients Using Artificial Intelligence
MR Based Survival Prediction of Patients With Primary Glioma Ssing Deep Learning or Machine Learning
Source: ClinicalTrials.gov · Last updated 8 Feb 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This registry aims to collect clinical, molecular and radiologic data including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2500 (estimated)
- First submitted
- 30 Dec 2019
- Start date
- 1 Jan 2017
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Diseases
- Childhood cancers
- NCT number
- NCT04215211
What you commit to
- Study type: Observational
- Planned participants: 2500
- From 1 Jan 2017 to the primary completion date, 1 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No gliomas
- No sufficient amount of tumor tissues for detection of molecular pathology
- Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic devices
- Patients who are pregnant or breast feeding
- Patients who are suffered from severe systematic malfuctions
Who the study is looking for
- Patients must have radiologically and histologically confirmed diagnosis of primary glioma
- Life expectancy of greater than 3 months
- Must receive tumor resection
- Signed informed consent
Age in the registry: 1 year to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.